4523 Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,316.00 |
| 52 Week High | JP¥7,818.00 |
| 52 Week Low | JP¥4,316.00 |
| Beta | -0.14 |
| 1 Month Change | -7.08% |
| 3 Month Change | -24.98% |
| 1 Year Change | -38.19% |
| 3 Year Change | -34.30% |
| 5 Year Change | -48.13% |
| Change since IPO | 165.02% |
Recent News & Updates
Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Dec 05
Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Nov 21Recent updates
Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Dec 05Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Nov 21Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders
Nov 15Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 12Is Eisai (TSE:4523) Using Too Much Debt?
Oct 15Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Sep 20Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Sep 05Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Aug 08Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jul 25Is Eisai (TSE:4523) A Risky Investment?
Jul 11Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Jul 11Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark
Jun 10Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly
Apr 11Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Mar 18Eisai's (TSE:4523) Dividend Will Be ¥80.00
Mar 04Shareholder Returns
| 4523 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.5% | -2.1% | -1.9% |
| 1Y | -38.2% | 11.1% | 14.6% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 14.6% over the past year.
Price Volatility
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4523 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4523's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,067 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| 4523 fundamental statistics | |
|---|---|
| Market cap | JP¥1.22t |
| Earnings (TTM) | JP¥40.97b |
| Revenue (TTM) | JP¥753.22b |
29.7x
P/E Ratio1.6x
P/S RatioIs 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 income statement (TTM) | |
|---|---|
| Revenue | JP¥753.22b |
| Cost of Revenue | JP¥157.26b |
| Gross Profit | JP¥595.97b |
| Other Expenses | JP¥555.00b |
| Earnings | JP¥40.97b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | 145.34 |
| Gross Margin | 79.12% |
| Net Profit Margin | 5.44% |
| Debt/Equity Ratio | 21.7% |
How did 4523 perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield112%
Payout RatioDoes 4523 pay a reliable dividends?
See 4523 dividend history and benchmarks| Eisai dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | May 29 2025 |
| Days until Ex dividend | 97 days |
| Days until Dividend pay date | 159 days |
Does 4523 pay a reliable dividends?
See 4523 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 18:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eisai Co., Ltd. is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |